Blue Trust Inc’s Recursion Pharmaceuticals RXRX Stock Holding History

Blue Trust Inc’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.34K	Hold	324	–	–	﹤0.01%	2125
2026 Q2	$1.19K	Buy	324 +150	+86%	+$499	﹤0.01%	2267
2026 Q1	$534	Buy	+174	New	+$672	﹤0.01%	2336
2025 Q2	–	Sell	-1,382	Closed	-$7.31K	–	2586
2025 Q1	$7.31K	Hold	1,382	–	–	﹤0.01%	2017
2024 Q4	$9.34K	Buy	1,382 +1,296	+1,507%	+$8.71K	﹤0.01%	1958
2024 Q3	$645	Buy	86 +53	+161%	+$380	﹤0.01%	2763
2024 Q2	$329	Buy	+33	New	+$288	﹤0.01%	2638
2023 Q2	–	Sell	-22	Closed	–	–	2453
2023 Q1	$0	Buy	+22	New	+$175	﹤0.01%	2581

Other funds holding RXRX

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

CCIA

Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return

WWM

Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return

Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return

AWM

Accel Wealth Management Waverly, Iowa $464M AUM 21.88% 1-Year Est. Return

Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

TWM

TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Blue Trust Inc's RXRX Position: Q3 2026 in Review

Blue Trust Inc held its Recursion Pharmaceuticals (RXRX) position steady in Q3 2026 at 324 shares worth $1.34K. The position accounts for ﹤0.01% of the portfolio, ranked #2125.

Blue Trust Inc first reported a position in RXRX in Q1 2023 and has held it in 8 quarters since. The position peaked at $9.34K in Q4 2024. 22 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

Blue Trust Inc held 324 shares of Recursion Pharmaceuticals worth $1.34K as of Q3 2026.
Blue Trust Inc left its Recursion Pharmaceuticals share count unchanged in Q3 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Blue Trust Inc's portfolio in Q3 2026, its #2125 holding.
Blue Trust Inc first reported a position in Recursion Pharmaceuticals in Q1 2023 and has held it in 8 quarters since.
Blue Trust Inc's Recursion Pharmaceuticals position peaked at $9.34K in Q4 2024.
22 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Blue Trust Inc's 13F filing for Q3 2026, filed 15 Oct 2026.